NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
Fate Therapeutics
Silverback Therapeutics
Western Regional Medical Center
National Cancer Institute (NCI)